INTERPACE BIOSCIENCES, INC. Files 8-K on Shareholder Vote Matters
Ticker: IDXG · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1054102
| Field | Detail |
|---|---|
| Company | Interpace Biosciences, Inc. (IDXG) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
INTC shareholders are voting on something important, details to follow.
AI Summary
On November 12, 2024, INTERPACE BIOSCIENCES, INC. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing indicates a shareholder meeting or vote is scheduled, though specific details of the proposals or outcomes are not provided in this excerpt.
Why It Matters
This filing signals that INTERPACE BIOSCIENCES, INC. is engaging in a formal process requiring shareholder approval, which could impact corporate governance or strategic direction.
Risk Assessment
Risk Level: medium — Shareholder votes can lead to significant changes in company direction, management, or financial structure, introducing uncertainty.
Key Players & Entities
- INTERPACE BIOSCIENCES, INC. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
- 0-24249 (other) — Commission File Number
- 22-2919486 (other) — IRS Employer Identification No.
FAQ
What specific matters are being submitted for a vote of security holders?
The provided excerpt does not specify the exact matters being submitted for a vote, only that such a submission is occurring.
When is the shareholder meeting or vote expected to take place?
The filing states November 12, 2024, as the date of the earliest event reported, but does not explicitly state the date of the vote itself.
What is the purpose of this 8-K filing?
The purpose is to report the submission of matters to a vote of security holders, as required by SEC regulations.
Has INTERPACE BIOSCIENCES, INC. previously undergone name changes?
Yes, the company was formerly known as Interpace Diagnostics Group, Inc. (name change 20151223), PDI INC (name change 20021113), and PROFESSIONAL DETAILING INC (name change 19980129).
What is the primary business of INTERPACE BIOSCIENCES, INC.?
The company is classified under SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-11-13 16:15:41
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-045132.txt ( ) — 205KB
- idxg-20241112.xsd (EX-101.SCH) — 3KB
- idxg-20241112_lab.xml (EX-101.LAB) — 33KB
- idxg-20241112_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Waterview Plaza , Suite 310 2001 Route 46 , Parsippany , NJ 07054 (Address, including zip code, of Principal Executive Offices) (855) 776-6419 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 12, 2024, the Company held its 2024 annual meeting of stockholders (the " 2024 Annual Meeting "). The following proposal was voted on and was approved by the Company's stockholders at the 2024 Annual Meeting with the stockholders having voted as set forth below: I. Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstain Broker Non-Vote 10,973,903 13,711 2,680 0 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Interpace Biosciences, Inc. By: /s/ Thomas W. Burnell Name: Thomas W. Burnell Title: President and Chief Executive Officer Date: November 13, 2024